About torpalimab
PD-1 immune checkpoint inhibitor
Used for
- Treatment of unresectable or metastatic nasopharyngeal carcinoma in adults, usually with chemotherapy.
- Other approved cancer uses depend on the country and treatment setting.
Usual adult dose
Commonly 240 mg by intravenous infusion every two weeks; dose and schedule depend on the cancer regimen and local approval.
Common side effects
- Fatigue, fever, rash, itching, or diarrhea
- Nausea, reduced appetite, or infusion reactions
- Immune-related inflammation of the lungs, bowel, liver, kidneys, or skin
- Thyroid or other hormone-gland problems
Important warnings
- Immune reactions can be severe or life-threatening and may occur after treatment ends.
- Report breathing problems, persistent diarrhea, jaundice, severe rash, or unusual weakness promptly.
- Treatment requires monitoring; infusion reactions may occur.
- Use only under cancer-specialist supervision.
Pregnancy
May harm an unborn baby; pregnancy testing and effective contraception are generally recommended during treatment and for four months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for four months after the last dose.
Interactions
- Other medicines that suppress the immune system may affect treatment or increase risks.
- Tell the oncology team about all medicines, supplements, and recent or planned transplants.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.